Login
Ocugen, Inc. logo

Ocugen, Inc.

ocugen.com

What Do They Do?

Develops gene therapies for inherited retinal diseases and other causes of blindness, including retinitis pigmentosa, Stargardt disease and geographic atrophy.

How Do They Make Money?

Ocugen earns collaborative-arrangement revenue from a partner as it carries out work under the arrangement; the amount is tied to its progress, measured against estimated total costs.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $67.8M in FY2025.

Operating income, FY2025
−1426% of revenue
▼ −15% (Loss) vs FY2024 (−$54.8M, −1350%)
Net income, FY2025
−1537% of revenue
▼ −26% (Loss) vs FY2024 (−$54.1M, −1333%)
Free cash flow, FY2025
−1295% of revenue
▼ −26% (Loss) vs FY2024 (−$45.5M, −1123%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +11%
vs $1.8M in Q3 FY2025
  • Nov 10, 2026 Licensed OCU400 rights to Celairis in Australia, New Zealand and ASEAN markets Ocugen is eligible for fees, milestone payments, sales royalties and a share of gross profits; it retains manufacturing rights.
  • Oct 13, 2026 Licensed OCU400 rights to Roots in the Middle East and North Africa Roots will handle regional regulatory submissions and commercialization; Ocugen will manufacture and supply the product.

Vaccine programs The older report included COVAXIN and an inhaled vaccine pipeline alongside gene and cell therapies. The latest report describes the inhaled vaccine platform but no longer lists COVAXIN.

Emphasis on blindness therapies The older report presented gene therapies, cell therapy and vaccines as multiple pipeline areas. The latest report centers its overview on modifier gene therapies for retinal diseases and blindness.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support